Relmada Therapeutics
RLMD
97 hedge funds and large institutions have $467M invested in Relmada Therapeutics in 2021 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 27 increasing their positions, 24 reducing their positions, and 16 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
163% more call options, than puts
Call options by funds: $4.18M | Put options by funds: $1.59M
78% more capital invested
Capital invested by funds: $263M → $467M (+$205M)
75% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 16
60.91% more ownership
Funds ownership: 57.4% → 118.31% (+61%)
13% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 24
11% more funds holding
Funds holding: 87 → 97 (+10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$44.5M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$36.6M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
+$19.6M |
| 4 |
VA
VR Adviser
New York
|
+$19.6M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$6.37M |
| 2 |
Alkeon Capital Management
New York
|
-$2.62M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$2.34M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.82M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.29M |
RLMD Hedge Fund Activity: Q4 2021 in Review
97 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q4 2021, worth a combined $467M — up 78% from $263M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new RLMD positions and 16 closed out — a net gain of 12 holders — while 27 added to existing stakes and 24 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $44.5M. The largest seller was Franklin Resources, exiting entirely with an estimated $6.37M sold.
- 97 institutional investors held Relmada Therapeutics (RLMD) as of Q4 2021, up from 87 in Q3 2021.
- Funds reported $467M of Relmada Therapeutics stock for Q4 2021, up 78% quarter-over-quarter.
- 28 funds opened new Relmada Therapeutics positions in Q4 2021 and 16 closed out, a net change of +12 holders.
- The largest Relmada Therapeutics buyer in Q4 2021 was RA Capital Management, an estimated $44.5M added.
- The largest Relmada Therapeutics seller in Q4 2021 was Franklin Resources, an estimated $6.37M sold.
Based on aggregated 13F filings for Q4 2021.